Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Higher Doses of Rituximab vs Standard Doses of Rituximab + CVP in Chronic ITP
NCT00774202Phase 3Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Nov 2003
- Primary completion
- Feb 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in immune thrombocytopenic purpura (ITP), sponsored by Weill Cornell Medicine. Started Nov 2003; status: completed.
02
Drugs
rituximab
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT00774202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00774202.